Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

NASDAQ: ONTX was devalued by  Zacks Research  from a “acquire” ranking to a “hold” rating in a research note issued to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on finding as well as creating little molecule drug prospects to treat cancer cells. The Company‘s items under different stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research experts also just recently commented on the business. Noble Financial editioned a “get” rating as well as issued a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating average price of $2.90 and a two-hundred day moving ordinary cost of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and an unfavorable net margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, compared to the consensus quote of $0.06 million. Throughout the exact same quarter in the previous year, the company published ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the current year.

A variety of hedge funds have actually just recently dealt shares of ONTX. GSA Funding Partners LLP bought a new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Funding Administration LP purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP got a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and other institutional capitalists own 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the recognition and also development of oncology therapeutics. It concentrates on finding and creating small molecule medication candidates to deal with cancer cells. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For additional information concerning research offerings from Zacks Investment Research, see Zacks.com.

This instantaneous information alert was created by narrative scientific research modern technology as well as financial information from Market in order to offer visitors with the fastest as well as most exact coverage. This tale was reviewed by Market’s content group prior to publication. 



Before you think about Onconova Therapeutics, you’ll intend to hear this.

Market tracks Wall Street’s top-rated and also best carrying out research analysts and also the stocks they advise to their customers on a daily basis. Market has actually determined the 5 stocks that cover experts are quietly whispering to their clients to acquire now before the broader market catches on … and Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics currently has a “Buy” score amongst analysts, top-rated experts think these 5 stocks are much better gets.